We have reported , in a randomized , controlled study , that tegafur-uracil ( UFT ) and protein-bound polysaccharide K ( PSK ) combination therapy significantly improves the 5-year disease-free survival rate and reduces the risk of recurrence compared to UFT alone for Stage II or III colorectal cancer .